Terms: = Ovarian epithelial cancer AND BRCA2, FAD, 675, ENSG00000139618, FACD, FAD1, FANCD, FANCD1, BRCC2, RP11-298P3_4 AND Clinical Outcome
105 results:
1. Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer.
Verdegaal EME; Santegoets SJ; Welters MJP; de Bruin L; Visser M; van der Minne CE; de Kok PM; Loof NM; Boekestijn S; Roozen I; Westra IM; Meij P; Van der Burg SH; Kroep JR
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37949617
[TBL] [Abstract] [Full Text] [Related]
2. Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and ovarian cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?
Infante M; Arranz-Ledo M; Lastra E; Abella LE; Ferreira R; Orozco M; Hernández L; Martínez N; Durán M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232793
[TBL] [Abstract] [Full Text] [Related]
3. Hyperthermic Intraperitoneal Chemotherapy in the Management of Primary epithelial ovarian cancer: A Debated Issue for Gynecologic Oncologists.
Gadducci A; Cosio S; Lippolis PV
Anticancer Res; 2022 Oct; 42(10):4659-4665. PubMed ID: 36191972
[TBL] [Abstract] [Full Text] [Related]
4. KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in ovarian cancer.
Liu H; Lin J; Zhou W; Moses R; Dai Z; Kossenkov AV; Drapkin R; Bitler BG; Karakashev S; Zhang R
Cancer Immunol Res; 2022 Aug; 10(8):1028-1038. PubMed ID: 35726891
[TBL] [Abstract] [Full Text] [Related]
5. CTLA-4 polymorphism contributes to the genetic susceptibility of epithelial ovarian cancer.
Chen J; Kang S; Wu J; Zhao J; Si W; Sun H; Li Y
J Obstet Gynaecol Res; 2022 May; 48(5):1240-1247. PubMed ID: 35150042
[TBL] [Abstract] [Full Text] [Related]
6.
Liontos M; Zografos E; Zoumpourlis P; Andrikopoulou A; Svarna A; Fiste O; Kunadis E; Papatheodoridi AM; Kaparelou M; Koutsoukos K; Thomakos N; Haidopoulos D; Rodolakis A; Dimopoulos MA; Zagouri F
Curr Oncol; 2021 Nov; 28(6):4446-4456. PubMed ID: 34898566
[TBL] [Abstract] [Full Text] [Related]
7. clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation - real life data.
Ataseven B; Tripon D; Schwameis R; Harter P; Rhiem K; Schneider S; Heikaus S; Baert T; Francesco AP; Heitz F; Traut A; Groeben HT; Schmutzler R; du Bois A
Gynecol Oncol; 2021 Dec; 163(3):569-577. PubMed ID: 34565600
[TBL] [Abstract] [Full Text] [Related]
8. Associations of preoperative serum high-density lipoprotein cholesterol and low-density lipoprotein cholesterol levels with the prognosis of ovarian cancer.
Lin Q; Liu W; Xu S; Sun L
Arch Gynecol Obstet; 2022 Mar; 305(3):683-691. PubMed ID: 34453586
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic/persistent/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3/RAD).
Macchia G; Jereczek-Fossa BA; Lazzari R; Cerrotta A; Deodato F; Ippolito E; Aristei C; Gambacorta MA; Scambia G; Valentini V; Ferrandina G
Int J Gynecol Cancer; 2022 Jul; 32(7):939-943. PubMed ID: 34155084
[TBL] [Abstract] [Full Text] [Related]
10. High grade, advanced, serous ovarian cancer with low serum CA125 levels.
Asali A; Haj-Yehia N; Zehavi T; Perry T; Beiner M; Fishman A; Kadan Y
J Obstet Gynaecol; 2021 Oct; 41(7):1107-1111. PubMed ID: 33427544
[TBL] [Abstract] [Full Text] [Related]
11. Significance of ERCC1 and Hormonal Receptor Expression in ovarian cancer.
El-Moniem Elrawi DA; El Khodary AI; Nassar HR; Darwish AD; Khorshed EN
J Med Invest; 2020; 67(3.4):391-398. PubMed ID: 33148925
[TBL] [Abstract] [Full Text] [Related]
12. Clear cell carcinoma of the ovary: a clinical and molecular perspective.
Iida Y; Okamoto A; Hollis RL; Gourley C; Herrington CS
Int J Gynecol Cancer; 2021 Apr; 31(4):605-616. PubMed ID: 32948640
[TBL] [Abstract] [Full Text] [Related]
13. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial.
Lee EK; Xiong N; Cheng SC; Barry WT; Penson RT; Konstantinopoulos PA; Hoffman MA; Horowitz N; Dizon DS; Stover EH; Wright AA; Campos SM; Krasner C; Morrissey S; Whalen C; Quinn R; Matulonis UA; Liu JF
Gynecol Oncol; 2020 Oct; 159(1):72-78. PubMed ID: 32771276
[TBL] [Abstract] [Full Text] [Related]
14. Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer.
Rusan M; Andersen RF; Jakobsen A; Steffensen KD
Eur J Cancer; 2020 Jan; 125():121-129. PubMed ID: 31865042
[TBL] [Abstract] [Full Text] [Related]
15. Ultrasound features and clinical outcome of patients with malignant ovarian masses diagnosed during pregnancy: experience of a gynecological oncology ultrasound center.
Moro F; Mascilini F; Pasciuto T; Leombroni M; Li Destri M; De Blasis I; Garofalo S; Scambia G; Testa AC
Int J Gynecol Cancer; 2019 Sep; 29(7):1182-1194. PubMed ID: 31326950
[TBL] [Abstract] [Full Text] [Related]
16. Magnetic resonance imaging radiomics in categorizing ovarian masses and predicting clinical outcome: a preliminary study.
Zhang H; Mao Y; Chen X; Wu G; Liu X; Zhang P; Bai Y; Lu P; Yao W; Wang Y; Yu J; Zhang G
Eur Radiol; 2019 Jul; 29(7):3358-3371. PubMed ID: 30963272
[TBL] [Abstract] [Full Text] [Related]
17. Oncologic and reproductive outcomes of cystectomy as a fertility-sparing treatment for early-stage epithelial ovarian cancer.
Kajiyama H; Suzuki S; Niimi K; Tamauchi S; Kawai M; Nagasaka T; Shibata K; Kikkawa F
Int J Clin Oncol; 2019 Jul; 24(7):857-862. PubMed ID: 30771039
[TBL] [Abstract] [Full Text] [Related]
18. Intraperitoneal α-Emitting Radioimmunotherapy with
Hallqvist A; Bergmark K; Bäck T; Andersson H; Dahm-Kähler P; Johansson M; Lindegren S; Jensen H; Jacobsson L; Hultborn R; Palm S; Albertsson P
J Nucl Med; 2019 Aug; 60(8):1073-1079. PubMed ID: 30683761
[TBL] [Abstract] [Full Text] [Related]
19. Calpain system protein expression and activity in ovarian cancer.
Zhang S; Deen S; Storr SJ; Chondrou PS; Nicholls H; Yao A; Rungsakaolert P; Martin SG
J Cancer Res Clin Oncol; 2019 Feb; 145(2):345-361. PubMed ID: 30448882
[TBL] [Abstract] [Full Text] [Related]
20. Identification of pathway-based recurrence-associated signatures in optimally debulked patients with serous ovarian cancer.
Deng K; Zhang F; Song W; Zhao W; Rong Z; Cai Y; Xu H; Lu M; Wang W; Li A; Hou Y; Li Z; Li K
J Cell Biochem; 2018 Nov; 119(10):8564-8573. PubMed ID: 30126000
[TBL] [Abstract] [Full Text] [Related]
[Next]
